Related Experiment Video
Updated: Sep 18, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
Daniel Zingg1,2,3, Chi-Chuan Lin4, Julia Yemelyanenko1,2
1Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Abstract:
Genetic alterations in receptor tyrosine kinase genes can generate potent oncogenic drivers. Truncation of the FGFR2 gene by its last exon 18 (E18) is caused by structural alterations, such as focal amplifications and gene fusions/rearrangements, as well as by mutations. All the E18-truncating FGFR2 variants (FGFR2ΔE18) act as strong driver alterations in cancer, and they commonly encode a receptor lacking the carboxy (C) terminal tail. In this study, we analyzed a compendium of Fgfr2-E18 variants to uncover the mechanism by which loss of the C-tail renders FGFR2 oncogenic. Although permutation of previously annotated C-terminal FGFR motifs did not recapitulate the tumorigenicity of FGFR2ΔE18, the functional annotation efforts led to the discovery of a C-terminal phenylalanine-serine motif that mediates binding of the C-tail to the kinase domain and thereby suppresses FGFR2 kinase activity. The permutation of this kinase domain-binding and suppression motif in conjunction with other FGFR2-regulatory C-terminal sites fully phenocopied the oncogenic competence of FGFR2ΔE18. Together, these findings delineate how the C-terminal tail prevents FGFR2 from aberrant oncogenic activation.
Significance:
A C-terminal phenylalanine-serine motif suppresses FGFR2 kinase activity by mediating binding of the C-terminal tail to the kinase domain, explaining how C-terminal truncation activates FGFR2 to promote tumorigenesis.
Insights
Truncation of the FGFR2 gene (FGFR2ΔE18) drives cancer by removing its C-terminal tail. A newly discovered motif in this tail suppresses FGFR2 activity, preventing oncogenic activation.
Area of Science:
- Oncogenic signaling pathways
- Molecular mechanisms of cancer development
- Receptor tyrosine kinase biology
Background:
- Genetic alterations in receptor tyrosine kinase genes are key drivers of cancer.
- FGFR2 gene truncations, specifically exon 18 (E18) deletions (FGFR2ΔE18), are potent oncogenic drivers.
- These variants often lack the C-terminal tail, but the mechanism of oncogenesis remains unclear.
Purpose of the Study:
- To elucidate the mechanism by which C-terminal tail loss activates FGFR2 oncogenesis.
- To identify functional motifs within the FGFR2 C-terminus responsible for suppressing kinase activity.
Main Methods:
- Analysis of a compendium of Fgfr2-E18 variants.
- Functional annotation and permutation of C-terminal FGFR motifs.
- Assessment of tumorigenicity and oncogenic competence of modified FGFR2 variants.
Main Results:
- Previously annotated C-terminal motifs did not explain FGFR2ΔE18 tumorigenicity.
- A novel C-terminal phenylalanine-serine motif was discovered that binds the kinase domain.
- This motif suppresses FGFR2 kinase activity; its permutation phenocopied FGFR2ΔE18 oncogenesis.
Conclusions:
- The C-terminal tail of FGFR2 contains a critical motif that suppresses its kinase activity.
- Loss of this motif, through C-terminal truncation, leads to aberrant FGFR2 activation and oncogenesis.
- Understanding this mechanism provides insights into FGFR2-driven cancers.
More Related Videos
09:40Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation
Published on: June 27, 2017
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Amplifying Signals via Enzymatic Cascade
TGF - β Signaling Pathway
MAPK Signaling Cascades
Receptor Tyrosine Kinases
The JAK-STAT Signaling Pathway
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...